Questions · Answered and cited
PT-141: Frequently Asked Questions
Direct, cited answers on the mechanism, the approved indication, the label dosage, the half-life, and the documented tolerability of bremelanotide.
What does the PT-141 peptide do?
PT-141 (bremelanotide) is a synthetic melanocortin MC3R/MC4R agonist that acts centrally in the brain to influence sexual desire and arousal [1]. It is FDA-approved only for HSDD in premenopausal women; all other uses are off-label [6]. It works on brain circuits, not blood flow, and does not raise testosterone [9].
How does PT-141 work?
It activates central melanocortin receptors — chiefly MC4R — in hypothalamic and limbic circuits, engaging dopaminergic pathways for sexual motivation [9]. Unlike PDE-5 inhibitors, it does not act on vascular blood flow [1]. An fMRI study showed it altered how the brain processes erotic stimuli in women with HSDD [5].
What receptors does PT-141 act on?
Primarily the melanocortin 4 receptor (MC4R), with secondary MC3R activity [1]. These subtypes are concentrated in the central nervous system, including the hypothalamus, which is why the drug's effect is central rather than peripheral [1]. The peripheral MC1R is the basis of its pigmentation effect [6].
Does PT-141 work through the brain or through blood flow?
Through the brain. Unlike PDE-5 inhibitors, which act peripherally on vascular smooth muscle, PT-141 acts centrally on the neural circuitry of sexual motivation [1]. An fMRI study in women with HSDD showed altered task-based brain processing of erotic stimuli under MC4R agonism [5].
What is a melanocortin receptor agonist?
A compound that activates one or more melanocortin receptors (MC1R-MC5R), the receptors that respond to peptides such as alpha-MSH [8]. PT-141 is a synthetic analogue of alpha-MSH that targets the central MC3R/MC4R subtypes [1]. The class spans sexual function, appetite, and pigmentation.
Does PT-141 increase testosterone?
No. PT-141 does not act via the hypothalamic-pituitary-gonadal axis and does not directly raise testosterone [9]. Its mechanism is central melanocortin signaling at MC4R/MC3R, not a hormonal or PDE-5 pathway [1]. The desire effect is a neural-circuit effect, not an endocrine one.
How is PT-141 different from PDE-5 inhibitors?
PDE-5 inhibitors (such as sildenafil) work peripherally on penile blood flow; PT-141 works centrally on brain circuits governing sexual desire [1]. They act through entirely different mechanisms, which is why one addresses physical erectile response and the other addresses desire [2].
Why does PT-141 cause nausea?
Nausea is the most common adverse event — about 40% over long-term use, and the leading reason participants discontinued — linked to central melanocortin activation [4]. It was the most common event in the Phase 3 trials [3]. This is a documented tolerability issue, not medical advice.
Does PT-141 cause skin darkening or hyperpigmentation?
Focal hyperpigmentation of skin, gums, and breasts is reported with repeated frequent dosing, attributed to MC1R activation [6]. It is one of the documented melanocortin-class effects and is recorded in the prescribing information. It is more likely with frequent administration [6].
Does PT-141 cause weight loss?
In two Phase 1 research trials in obese premenopausal women, high-frequency MC4R agonism reduced caloric intake and body weight (about -1.3 kg versus placebo over 16 days), reflecting MC4R's appetite role [10]. This is a research finding at a high-frequency protocol, not an approved use [10].
What is PT-141?
PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide and melanocortin MC3R/MC4R receptor agonist studied for sexual desire and arousal [1]. It is FDA-approved for HSDD in premenopausal women and acts centrally on the brain [6].
What is PT-141 peptide?
It is a seven-amino-acid cyclic peptide analogue of the natural hormone alpha-MSH, molecular weight about 1,025 Da [6]. The cyclic (lactam) structure improves stability over linear melanocortin peptides [6]. PT-141 is the lab designation; bremelanotide is the approved-drug name.
What is PT-141 used for?
It is FDA-approved only for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women [6]. Use in men, for erectile dysfunction, or in postmenopausal women is off-label and not supported by the approval; the male/erectile evidence is early-phase and investigational [6].
Is PT-141 the same as bremelanotide?
Yes. PT-141 is the research designation; bremelanotide is the international nonproprietary name (INN) for the same melanocortin receptor agonist [6]. The two names refer to one molecule. The approved finished drug is the bremelanotide injection product [6].
What is bremelanotide?
Bremelanotide is the approved-drug name for PT-141, a melanocortin MC3R/MC4R agonist approved in June 2019 (NDA 210557) for HSDD in premenopausal women [6]. It acts centrally on brain circuits governing sexual desire rather than on blood flow [1].
What is the PT-141 dosage?
The approved label specifies 1.75 mg subcutaneously as needed, no more than one dose per 24 hours and no more than 8 per month [6]. This is reported as the label figure, not a protocol for any reader to follow. Dosing decisions belong with a qualified clinician [6].
How much PT-141 should I take?
This digest reports only studied and labeled doses, not individual recommendations. The approved dose for the HSDD indication is 1.75 mg subcutaneous as-needed [6]. Dosing decisions belong with a qualified clinician; nothing here is a recommendation to use the compound.
How much PT-141 to inject?
The label and Phase 3 trials used 1.75 mg subcutaneously per dose [6]. Phase 2 dose-finding studied 0.75, 1.25, and 1.75 mg [3]. These are reported findings, not dosing instructions, and the approved product is a prefilled autoinjector rather than a reconstituted powder [6].
What is the PT-141 dosage for women?
For the approved HSDD indication in premenopausal women, the label dose is 1.75 mg subcutaneous as-needed, with the same per-24-hour and monthly maximums [6]. It is reported as the label figure only; this is the sole population for which a dose is FDA-approved [6].
How do you reconstitute PT-141?
The approved product is a prefilled subcutaneous autoinjector, not a reconstituted powder [6]. 'Research chemical' lyophilized PT-141 is a laboratory material outside the approval framework, and this digest does not provide preparation instructions [6]. Identity, purity, and concentration of such material are unregulated [6].
How do you take PT-141?
In the trials and label, bremelanotide is given subcutaneously as needed at least 45 minutes before anticipated sexual activity [6]. This describes the studied regimen for the approved indication, not a recommendation to self-administer [6]. The approved product is an autoinjector [6].
How often can you take PT-141?
The label limits dosing to no more than one dose per 24 hours and no more than 8 doses per month [6]. The per-24-hour limit is partly informed by the transient blood-pressure effect [6]. This is reported as the label limit only, not advice.